



BIO SERENITY

BioSerenity, a Medical Technology company specializing in remote diagnostic solutions, raises €65 million to extend its activity into the US and deepen its IoT and AI solutions.

Paris, June 18th 2019 – BioSerenity, a high growth French startup company that specializes in remote diagnostic technologies and has demonstrated expertise in digital health assessment and management, has raised €65 million (approx.\$73) in a Series B funding round, including €50 million in equity financing led by Dassault Systèmes and BioSerenity's existing investors Idinvest Partners, LBO France, and the PSIM fund, managed by Bpifrance. This fundraising will allow BioSerenity to extend its commercial activities internationally as well as broaden its Internet of Things (IoT) and Artificial Intelligence (AI) health care solutions.

BioSerenity offers medical solutions and remote diagnostics expertise in several chronic disease areas to enhance patient disease management by streamlining patient monitoring, increasing potential diagnostic yields, and, better supporting therapeutic decisions.


Since its creation, BioSerenity has aimed to simplify the acquisition and interpretation of electrophysiological signals for physicians and their chronic patients. BioSerenity began its activity in 2014 with medical solutions focused on electroencephalograms and as of today, is one of the leading telemedicine providers in this field.

BioSerenity is one of the few companies offering managed-care services to its customers, by developing front end to back end computer systems for monitoring solutions that are used as a companion diagnostic tool in combination with treatment. This also includes hardware medical devices, mobile apps, a secure online cloud, Artificial Intelligence, and remote specialist services for data analysis on a 24/7 basis.

As a result of a business model allowing for healthcare cost savings, BioSerenity operates with more than two hundred healthcare facilities around the globe, helping them to perform more efficient, yet less expensive, medical procedures. Such collaborations, in conjunction with strategic partnerships with pharmaceutical companies, help more than two thousand patients per month receive the proper diagnosis. BioSerenity's solutions allows optimization of patients' pathway in several disease areas (neurology, cardiology, sleep disorders, urology, and pregnancy monitoring), as a result of online based clinical tools and real-world evidence data collection.



According to Pierre-Yves Frouin, BioSerenity President and Chief Executive Officer, *“Our success is based on our development and business model focused on healthcare cost reduction and better patient management. We strive to understand the healthcare providers’ and patients’ issues in real life and we are committed to address them”*.



BIO SERENITY © a system allowing recordings in healthcare settings and at home, a mobile app allowing interaction with patients, an expert system with artificial intelligence to assist the diagnosis and remote experts available for second opinion or analysis. The aim of BioSerenity is to ensure the most efficient treatment as quickly as possible, anytime and anywhere.

A fundraising to accelerate growth

This new round of financing confirms investors’ trust in BioSerenity’s potential. For Pierre-Yves Frouin, *“with this fundraising, we reaffirm our global ambitions. We are pleased to receive the renewed trust of our investors and to welcome Dassault Systèmes, a worldwide leader of scientific and simulation software, with whom we plan to reinforce collaborations in the medical field”*.

“Healthcare industry growth will be led by connected medical devices offering possibilities to collect real-world patient data in a cost-effective, continuous way that ensures patient adherence and comfort, and helps the medical community diagnose and treat conditions early on, paving the way to outcome-based care. This is precisely the purpose of BioSerenity” said Claire Biot, Vice President, Life Sciences Industry, Dassault Systèmes.

Valéry Huot, Partner et Head of Venture at LBO France, reports: *“faithful to our strategy of supporting commercial stage growth companies, we are proud to pursue our partnership with BioSerenity’s team during a major step forward. With this new round financing, and after the 2017 €15 million fundraising round, BioSerenity is making important strides towards bringing telemedicine and medical solutions worldwide.”*

The funds will be used by the medical and telemedicine company to accelerate growth, especially at an international level, and to expand current solutions for cardiovascular, neurological, and sleep diseases through AI and digital biomarker detection, to develop new solutions in other therapeutic areas, and to develop new opportunities for telemedicine.

Pierre-Yves Frouin further states: *“we rely on a broad range of expertise, from pharmacists to engineers, from textile technicians to AI specialists. It is very rare for a company of our size to gather such diverse talents. Our skilled team, combined with our investors’ support allows us to continue pursuing the development of new healthcare solutions”*

“We are pleased to renew our confidence in BioSerenity’s management during this important step of their development. Our objective is to support innovative companies at each step of their growth, notably in their international development. We welcome the arrival of Dassault Systems, a French industrial group, worldwide leader in its category”, adds Emmanuel Audouard, PSIM Funds Director at Bpifrance.

Luc Maruenda, Partner from Idinvest Partners concludes: *"We support BioSerenity since its beginning and we are convinced that the public recognition of its technology will increase and thus accelerate its international development"*

Banking leverage

In addition to the equity funds, BioSerenity received the support of three French banks and the advice of BNP Paribas CIB Corporate Finance Digital: *"Our Corporate Finance team dedicated to startups and future digital champions has been delighted to act as financial advisor to this transforming transaction. This latest financing round confirms BioSerenity's maturity and market leadership, the relevance of its business model and its outstanding management and teams. A banking partner of BioSerenity since its early days through its WAI hub (Innovation specialized teams), BNPP Paribas is proud of contributing to the emergence of a French global leader delivering innovative and comprehensive solutions which are transforming the way patients are monitored and diagnosed. BioSerenity addresses one the major healthcare challenge in this century"* Antoine Joly, Director Digital Advisory, BNP Paribas Corporate and Institutional Banking

About Bioserenity

Founded in 2014 and headquartered in Paris, BioSerenity is an innovative company based in the Brain and Spine institute (icm-institute.org), with whom the company shares a common laboratory around artificial intelligence and digital biomarkers' detection. Active in three continents, the aim of BioSerenity is to create connected medical solutions in partnership with healthcare facilities and industries to help the diagnosis and the monitoring of patients with chronic diseases in cardiology, neurology, sleep disorders, urology, and pregnancy. BioSerenity and its subsidiary Serenity Medical Services work today with more than 200 hospitals in France and in the USA to help diagnostics and complex monitoring. BioSerenity proposes the acquisition of electrophysiological exams, frequent, and long-term monitoring through connected medical devices and trained technologists on the field. Remote expert physicians are also available anytime and anywhere for data interpretation.

For more information: www.bioserenity.com

Contact : contact@bioserenity.com

Phone : +33.1.83.85.97.25

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes' collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 250,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.

Dassault Systèmes Press Contacts

Corporate / France	Arnaud MALHERBE	arnaud.malherbe@3ds.com	+33 (0)1 61 62 87 73
North America	Suzanne MORAN	suzanne.moran@3ds.com	+1 (781) 810 3774
EMEAR	Virginie BLINDENBERG	virginie.blindenberg@3ds.com	+33 (0) 1 61 62 84 21
China	Grace MU	grace.mu@3ds.com	+86 10 6536 2288
India	Santanu BHATTACHARYA	santanu.bhattacharya@3ds.com	+91 124 457 7111
Japan	Yukiko SATO	yukiko.sato@3ds.com	+81 3 4321 3841
Korea	Hyunkyung CHAE	hyunkyung.chae@3ds.com	+82 2 3271 6653
AP South	Magdalene TAN	magdalene.tan@3ds.com	+65 9487 1206

About Idinvest

Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997, Idinvest Partners used to belong to the Allianz Group until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners became a subsidiary of Eurazeo, a leading global investment company, with a diversified portfolio of €17bn in assets under management, including approximately €11bn from investment partners, invested in over 350 companies.

Luc Maruenda, Partner, lm@idinvest.com

www.idinvest.com

About LBO France / Innovation Capital

As a key player in private equity with €4bn of capital under management, LBO France is an independent company that has been supporting French and Italian companies in their growth for more than 30 years. Its investment strategy is built on 4 distinct segments managed by dedicated teams: (i) Mid Cap Buyout through the White Knight funds and Small Cap Buyout through the Hexagone/Small Caps Opportunities funds, (ii) Venture Capital through the SISA/Digital Health funds, (iii) Real Estate through the White Stone and Lapillus funds, (iv) Debt. LBO France is 100% owned by its management and employs nearly 60 professionals.

Contact :

Valery Huot, Partner – Head of Venture - valery.huot@lbofrance.com

Press contact : Citigate Dewe Rogerson

Robert Amady - +33 1 53 32 78 91 - +33 6 72 63 08 91 - robert.amady@citigate.fr

Daiana Hirte - +33 1 53 32 78 90 - +33 7 60 90 89 12 - daiana.hirte@citigate.fr

www.lbofrance.com

About Bpifrance

Bpifrance fund companies – in every step of their development- in credit, guarantee, and equity. Bpifrance supports them in their innovation projects and in their international launch. Bpifrance also ensures their export activities through a large panel of products. Consulting, universities, networking, and acceleration programs for startups, SMEs and Midcaps are also part of our offers to entrepreneurs. Thanks to Bpifrance and its 48 regional locations, entrepreneurs profit from close, unique, and efficient discussion with their partner to support them in their challenges.

For information on : www.Bpifrance.fr - <https://presse.bpifrance.fr/>

Follow us on Twitter : @Bpifrance - @BpifrancePresse

Press Contact : nathalie.police@bpifrance.fr – Tel : +33 1 41 79 95 26

About the Investissements d'Avenir Program:

With €57 billion, the Investissement d'Avenir Program, driven by the Investment general secretary, has been implemented by the French government to finance innovative and promising investments in the French territory. Six national priorities have been identified to allow France to increase its growth and employment potential:

- Higher education, research and education
- Research development and transfer to the economic world
- Sustainable development
- SME and industry
- Digital economy
- Healthcare and biotechnology

LE GRAND PLAN
D'INVESTISSEMENT

The third section of the Investissement d'Avenir Program, PIA3, is enshrined in the Grand Plan d'Investissement, introduced by the French prime minister on September 25th, 2017.

To learn more about the investissements d'avenir program: <http://www.gouvernement.fr/secretariat-general-pour-l-investissement-sgpi> Twitter : @SGPI_avenir